3 New Strong Buy Ratings from Top-Rated Analysts: 09/12/2025

By Mijuško Šibalić, Stock Market Writer and Stock Researcher

September 16, 2025 6:41 AM UTC

3 New Strong Buy Ratings from Top-Rated Analysts: 09/12/2025

Speed up your stock research with the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener. Here’s what’s trending right now:

Analyst forecasts suggest Theravance Biopharma (TBPH) could nearly double in the coming year
Cirrus Logic (CRUS) offers a unique way to invest in an essential corner of the semiconductor market.
Tapestry (TPR) has gained over 30% since we added it to the Zen Investor portfolio. Here’s why the move may not be over.

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

Valuation Up 5,000%. Shares Now $0.85 - Still Early? RAD Intel has emerged as a critical player in the AI infrastructure powering digital advertising. It's already working with Fortune 1000 clients, fueling their marketing performance through a proprietary AI decision layer that delivers results-not hype. Backed by multiple Fidelity funds, supported by venture investors, and selected by the Adobe Design Fund, RAD Intel attracts early investors - including operators from Google, Meta, YouTube, and Amazon - who spot inflection points early. RAD Intel has raised over $60 million and grown its valuation over 5,000% in under four years. The share price recently increased to $0.85, reflecting the company's momentum-but there's still limited allocation available. Over 14,000 investors have already moved. If you're still watching from the sidelines, now may be the time to act. View the investor brief and lock in $0.85 shares while the current allocation remains open. *This valuation has been set by RAD Intel. DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A+ offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radintel.ai.

1. Theravance Biopharma (NASDAQ: TBPH)

Theravance Biopharma focuses on developing and commercializing respiratory and inflammation therapies. The company maintains a lean business model that relies significantly on royalties and a streamlined pipeline. Wall Street is quite confident that the stock will soar — TBPH is currently trading at quite an attractive valuation and has a hefty checkbook to back it up.

Zen Rating: A (Strong Buy) — see full analysis >

Recent Price: $14.30 — get current quote >

Max 1-year forecast: $28.00

Why we’re watching:

Analyst coverage of TBPH is unanimously bullish — at present, 3 equity researchers issue ratings for the stock, and all 3 of them have given it a Strong Buy rating. See the ratings
Moreover, the average 12-month price forecast for Theravance Biopharma shares is currently pegged at $25.67, which implies a hefty 79.49% upside.
Mayank Mamtani of B. Riley Securities (a top 4% rated analyst) recently initiated coverage on TBPH with a Strong Buy rating and a Street-high $28 price target.
Mamtani called Theravance Biopharma a fully integrated biopharma company with a track record of discovering, developing, and commercializing respiratory therapies.
Now that the company has monetized its non-core asset Trelegy, it is well positioned to benefit from a recent strategic review process aimed at unlocking shareholder value, the analyst told readers.
Our rating system, Zen Ratings, takes into account 115 factors when evaluating stocks. Equities that rank in the top 5%, like Theravance Biopharma, have a Zen Rating of A and have provided an average annual return of 32.52% since the early 2000s. TBPH actually ranks in the top 1% — it is rated 18th overall out of the 4,600 stocks that we keep track of.
Each Zen Rating is a composite score of 7 Component Grade ratings. For example, TBPH ranks in the 92nd percentile in terms of Value.
Growth and Financials are Theravance Biopharma’s strongest suits, however — in these categories, the stock ranks in the top 4% and 3% of equities, respectively. (See all 7 Zen Component Grades here >)

2. Cirrus Logic (NASDAQ: CRUS)

Our next pick designs the high-performance mixed-signal chips that power things like sound quality, voice recognition, and power management in smartphones, earbuds, and laptops. While it might not attract any headlines, Cirrus Logic offers a unique way to invest in an essential corner of the semiconductor market.

Zen Rating: B (Buys) — see full analysis >

Recent Price: $116.79 — get current quote >

Max 1-year forecast: $130.00

Why we’re watching:

CRUS shares are tracked by 3 Wall Street analysts, whose coverage is split between 2 Strong Buy ratings and 1 Hold rating. See the ratings
Stifel Nicolaus equity researcher Tore Svanberg (a top 1% rated analyst) recently maintained a Strong Buy rating on the stock and increased his price target from $120 to a Street-high $130.
Svanberg said Cirrus Logic is "ideally-placed to benefit" from the new trend of speech as a key Human-Machine/AI Interface on laptops, noting that it already sells to the top five laptop PC OEMs and is featured in laptops made by its biggest customer.
Cirrus Logic ranks in the 91st percentile of the stocks that we track, giving it a Zen Rating of B, which has historically corresponded to an average annual return of 19.88%.
CRUS is currently trading at a very modest price-to-earnings (P/E) ratio of 17.62x — so it’s no wonder that it ranks in the top 4% when it comes to Value.
In addition, the company’s strong balance sheet, exemplified by a debt-to-equity ratio of just 0.19, means that it ranks in the top 1% in terms of Financials. (See all 7 Zen Component Grades here >)

A note from our sponsors...

What's Nvidia's Dirty Secret? Nvidia's charging into two seismic tech frontiers projected to be worth over $24 TRILLION! And they're in a race to dominate first. But here's the dirty secret Nvidia won't admit... They can't do it alone. Nvidia needs 3 Silent Partners... This $24 trillion pivot hinges on them. Click here now and find out about 3 companies critical to Nvidia's success in 2026.

3. Tapestry (NASDAQ: TPR)

Tapestry (TPR), a suite of luxury retail brands, has gained over 30% since we added it to the Zen Investor portfolio. But the move may not be over. It delivered a strong double beat in its last quarterly report; when you factor in a robust direct-to-consumer model, strong growth in online sales, and ambitious forecasts, it’s clear why Tapestry deserves a closer look.

Zen Rating: A (Strong Buy) — see full analysis >

Recent Price: $106.47 — get current quote >

Max 1-year forecast: $142.00

Why we’re watching:

TPR shares have 7 Strong Buy ratings, 3 Buy ratings, and 2 Hold ratings. See the ratings
In addition, the average price target for Tapestry stock, currently set at $114, implies a healthy 7.07% upside.
JP Morgan researcher Matthew Boss (a top 10% rated analyst) maintained a Strong Buy rating on the stock following Tapestry's 2025 Investor Day event on 2025/09/10. and increased his price target from $139 to a Street-high $142.
According to the analyst, the company's three-year strategy is really "the floor" from which there is room to grow.
Tapestry is currently the 2nd highest-rated stock in the Luxury industry, which has an Industry Rating of A.
TPR ranks in the 95th percentile of the stocks that we track, giving it a Zen Rating of A.
In terms of both Growth and Safety, Tapestry shares rank in the 85th percentile of equities. Financials are TPR’s biggest strength — as the stock ranks in the top 3% in this category.
Owing to the above fundamentals, it’s no surprise Tapestry (TPR) has gained over 30% since we added it to the Zen Investor portfolio — add it to your watchlist now to see what happens in the coming weeks and months.